Drug Profile


Alternative Names: PresbiDrops (CSF-1)

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Orasis Pharmaceuticals
  • Class Miotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 01 Dec 2016 Orasis Pharmaceuticals initiate a phase IIa trial for Presbyopia in Israel (Ophthalmic) (NCT02965664)
  • 16 Nov 2016 Orasis Pharmaceuticals plans a phase IIa trial for Presbyopia in Israel (Ophthalmic) (NCT02965664)
  • 01 Jul 2016 Phase-II clinical trials in Presbyopia in Israel (Ophthalmic) (NCT02745223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top